Amarantus Bioscience acquires option to license Alzheimer's IP of Dr. Arendt Amarantus Bioscience announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3rd Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development. Dr. Arendt has filed international patent applications on the concepts of modulating the expression of P16 in the brains of patients of Alzheimer's disease using gene therapy. P16 is a cell cycle protein that assists in maintaining and nurturing synaptic connections that is hypothesized to be at the root of Alzheimer's pathology. The company is currently developing an Alzheimer's blood diagnostic LymPro Test capable of identifying cell cycle dysregulation by harvesting peripheral blood lymphocytes. This option agreement opens the possibility of a targeted therapeutic on those Alzheimer's patients that have tested positive for LymPro.
Amarantus Bioscience's Eltoprazine receives FDA Orphan Drug Designation Amarantus BioScience has received orphan drug designation from the FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia. Amarantus published positive results from a Phase 2 initial proof-of-concept clinical study in February of 2015 in the journal Brain, and highlighted the publication of two independent peer-reviewed scientific publications describing the mechanism of action of eltoprazine for the treatment of PD LID in August of 2015 and December 2016.